| Name | GSK682753A |
|---|---|
| Synonyms |
EBI2 inhibitor GS682753A
GSK-682753A,GSK682753A (E)-8-(3-(4-Chlorophenyl)acryloyl)-3-(3,4-dichlorobenzyl)-1-oxa-3,8-diazaspirodecan-2-one (E)-8-(3-(4-Chlorophenyl)acryloyl)-3-(3,4-dichlorobenzyl)-1-oxa-3,8-diazaspirodecan-2-one , GSK682753A 1-Oxa-3,8-diazaspirodecan-2-one, 8-[(2E)-3-(4-chlorophenyl)-1-oxo-2-propen-1-yl]-3-[(3,4-dichlorophenyl)methyl] |
| Description | GSK682753A is a selective and highly potent inverse agonist of the epstein-barr virus-induced receptor 2 (EBI2) with an IC50 of 53.6 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 53.6 nM (EBI2)[1] |
| In Vitro | GSK682753 is a selective and highly potent inverse agonist for murine as well as human EBI2 with inhibition of G protein-dependent signals as well as signals that are probably G protein-independent. In cAMP-response element-binding protein-based reporter and guanosine5'-3-O-(thio)-triphosphate (GTPγS) binding assays, the potency of this compound is 2.6-53.6 nM, and its inhibitory efficacy is 75%. GSK682753A dose-dependently inhibits EBI2 with an IC50of 53.6 nM. GSK682753A inhibits ERK phosphorylation, GTPγS binding, and cAMP-response element-binding protein activation with similar potency[1]. |
| Cell Assay | The effect of GSK682753A on cAMP-induced CREB activation is measured. GSK682753A at varying concentrations is added when the transfection is stopped with a DMSO concentration after compound addition of 0.1%. The CREB activity is determined 24 h after transfection using the LucLite substrate[1]. |
| Molecular Formula | C23H21Cl3N2O3 |
|---|---|
| Molecular Weight | 479.78 |
| Storage condition | 2-8℃ |
| Water Solubility | DMSO: ≥ 27 mg/mL |